Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04779489 · ClinicalTrials.gov registry record · NA
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04779489 is a NA study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT04779489, a NA study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy. Immune checkpoint inhibitor (ICI) therapy is FDA-approved in advanced bladder cancer for patients unable to receive or failing to respond to platinum-based chemotherapy. The present study seeks to determine if next-generation radiation therapy (personalized ultrafractionated stereotactic ablative radiotherapy, or PULSAR) is feasible and effective in patients receiving ICI for bulky cN+ bladder cancer.
Interventions
- RADIATION personalized ultrafractionated stereotactic ablative radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-09-06 |
| Est. Completion | 2023-06-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04779489
The ClinicalTrials.gov registry entry for NCT04779489 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which personalized ultrafractionated stereotactic ablative radiotherapy is the first listed.
NCT04779489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04779489 about?
NCT04779489 is a clinical study titled "Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer". Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy. Immune checkpoint inhibitor (ICI) therapy is FDA-approved in advanced bladder cancer for patients unable to receive or failing to r...
What is the current status of trial NCT04779489?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2021-09-06. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT04779489?
The interventions under investigation include: personalized ultrafractionated stereotactic ablative radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT04779489?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.